AVXL Healthcare

Anavex Life Sciences Corp.

$1.20+5.26%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 111.2M USD
Enterprise value: -2.5M USD
Full-time employees: 34

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 19% from September 2022 to August 2026.
Anavex Life Sciences had 19% more shares at August 2026 than at September 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Anavex Life Sciences had 19% more shares at August 2026 than at September 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
Anavex Life Sciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Anavex Life Sciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Anavex Life Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $7.8M profit in the quarter to June 2026.
Anavex Life Sciences reported a net loss over the last twelve months, but its most recent quarter was profitable ($7.8M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

StockQuotient Score

—

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 100.1% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-26.3%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield101.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.14

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.53Sector median: 0.6250 · MAD: 0.3380

Current ratio15.62×

Yahoo Finance fallback · SEC figure unavailable or out of dateReported value33% base weight · Z-score 9.41Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Anavex Life Sciences

Is Anavex Life Sciences getting weaker?: Its latest SEC filing (Aug 28, 2026) got weaker in some ways: share count up 100.1%.
How is Anavex Life Sciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -11.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.7% vs peers 1.5% (weaker than 100% of peers).
Is Anavex Life Sciences growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Anavex Life Sciences?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Anavex Life Sciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 15.62× vs a peer median of 2.59× (stronger than 93% of peers).Current ratio 15.62× vs peers 2.59× (stronger than 93% of peers). Beta 1.14 vs a peer median of 0.63 (weaker than 77% of peers).Beta 1.14 vs peers 0.63 (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 28, 2026 · compared with the quarter ended Dec 31, 2025

Got weaker

Share count up 100.1% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Net income (12 months)	−39.9M USD	−13.0M USD	−67.4%
Cash	131.7M USD	118.3M USD	−10.2%
Shares outstanding	92.7M	185.4M	+100.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Sep 2021	FY Sep 2022	FY Sep 2023	FY Sep 2024	FY Sep 2025	Change
Return on assets (ROA)	-23.5%	-31.4%	-30.8%	-31.7%	-44.7%	▼ 13 pts
Return on equity (ROE)	-25.1%	-33.7%	-33.5%	-35.8%	-48.9%	▼ 13 pts

AVXL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Shareholders being diluted. Shares outstanding up 19% from September 2022 to August 2026.

Anavex Life Sciences had 19% more shares at August 2026 than at September 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Anavex Life Sciences had 19% more shares at August 2026 than at September 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

Anavex Life Sciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Anavex Life Sciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Anavex Life Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $7.8M profit in the quarter to June 2026.

Anavex Life Sciences reported a net loss over the last twelve months, but its most recent quarter was profitable ($7.8M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

Questions investors ask about Anavex Life Sciences

Is Anavex Life Sciences getting weaker?

Its latest SEC filing (Aug 28, 2026) got weaker in some ways: share count up 100.1%.

How is Anavex Life Sciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -11.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.7% vs peers 1.5% (weaker than 100% of peers).

Is Anavex Life Sciences growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Anavex Life Sciences?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Anavex Life Sciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 15.62× vs a peer median of 2.59× (stronger than 93% of peers).Current ratio 15.62× vs peers 2.59× (stronger than 93% of peers). Beta 1.14 vs a peer median of 0.63 (weaker than 77% of peers).Beta 1.14 vs peers 0.63 (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−39.9M USD

−13.0M USD

−67.4%

Cash

131.7M USD

118.3M USD

−10.2%

Shares outstanding

92.7M

185.4M

+100.1%

Key ratios

FY Sep 2021

FY Sep 2022

FY Sep 2023

FY Sep 2024

FY Sep 2025

Change

Return on assets (ROA)

-23.5%

-31.4%

-30.8%

-31.7%

-44.7%

▼ 13 pts

Return on equity (ROE)

-25.1%

-33.7%

-33.5%

-35.8%

-48.9%

▼ 13 pts